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The Sentry inferior vena cava (IVC) filter is designed to provide temporary protection from pulmonary embolism (PE) and then
bioconvert to become incorporated in the vessel wall, leaving a patent IVC lumen. Objective. To evaluate the performance and
stages of incorporation of the Sentry IVC filter in an ovine model. Methods. Twenty-four bioconvertible devices and 1 control
retrievable filter were implanted in the infrarenal IVC of 25 sheep, with extensive daily monitoring and intensive imaging. Vessels
and deviceswere analyzed at early (≤98 days,n= 10) and late (180± 30 days, n= 14 study devices, 1 control) termination and necropsy
time-points. Results.Deployment success was 100%with all devices confirmed in filtering configuration, there were no filter-related
complications, and bioconversionwas 100% at terminationwith vessels widely patent. By 98 days for all early-incorporation analysis
animals, the stabilizing cylindrical part of the Sentry framewas incorporated in the vessel wall, and the filter armswere retracted. By
180 days for all late-incorporation analysis animals, the filter arms as well as frames were stably incorporated. Conclusions.Through
180 days, there were no filter-related complications, and the study devices were all bioconverted and stably incorporated, leaving
all IVCs patent.
1. Introduction
Pulmonary embolism (PE) leads to the hospitalization or
death of approximately 225,000 Americans, 30,000 Cana-
dians, and 300,000 Europeans per year, with the incidence
having increased during the past decade [1, 2]. In the United
States, annual estimates of the nonfatal occurrence of PE
range from400,000 to 630,000 [3], and it is themost common
preventable cause of hospital-related death [4, 5]. Risk factors
for PE include a history of deep vein thrombosis (DVT),
major hospitalization and recent surgical procedures, trau-
matic injury, and prolonged inactivity or immobility [6]. The
established primary treatment for venous thromboembolic
(VTE) disease including PE and DVT is pharmacologic
management with anticoagulant agents. However, in many
patients anticoagulation is contraindicated during periods
of high PE risk, and inferior vena cava (IVC) filters are
recommended for these situations [3, 7–9].
In response to complications such as IVC thrombosis
and perforation that have been associated with the originally
developed IVC filters intended for permanent placement,
various optional or retrievable IVC filters have become
available since 2003 to provide protection from PE during
recognized periods of transient risk, after which they are
meant to be removed [10]. In practice, however, these filters
have not been routinely retrieved, and while remaining
indwelling, they have been associated with a time-dependent
increase in retrievable-filter-specific complications including
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Figure 1: Sentry IVC filter in filtering (left) and bioconverted (right)
configurations.
device tilting, fracture, migration, embolization, thrombosis,
IVC perforation, surgery, and death [4, 11–15]. In April
2010, the US Food and Drug Administration (FDA) issued
a safety communication (which was updated in May 2014)
recommending that physicians “consider removing the filters
as soon as protection from pulmonary embolism is no longer
needed” [9, 16, 17]. According to a subsequently published
FDA decision analysis, the benefit/risk profile begins to favor
filter removal between 29 and 54 days after device implan-
tation [16]. Nevertheless, even with a consequent increase of
education and patient-tracking initiatives, as many as 65% to
80% of filters remain unretrieved [4, 12–15].
The Sentry IVC filter (Novate Medical Ltd, Galway,
Ireland) is designed to provide temporary protection from
PE during transient high-risk periods and then to bioconvert,
thus avoiding the need for a second (retrieval) intervention
while leaving a patent IVC lumen. Within a stabilizing
cylindrical nitinol frame, the Sentry filter cone is formed by
6 pairs of arms held together at an apex in the center of the
lumen by a bioabsorbable filament (Figure 1). Bioconversion
is achieved with the hydrolysis of the filament material
allowing the filter arms to retract to the IVC wall, where they
are incorporated along with the cylindrical frame, leaving the
vessel lumen patent.The endothelialization of the device after
the bioconversion and retraction of the arms is expected to
limit the likelihood of late filter-related complications. The
objective of this preclinical studywas to evaluate the technical
performance, stages of incorporation, and any device-related
complications associated with the Sentry IVC filter in an
ovine model with intensive in vivo and ex vivo imaging
analysis.
2. Materials and Methods
2.1. Device Description. The Sentry IVC filter consists of a
laser-cut one-piece nitinol device, comprising a cylindrical
frame and a filter cone formed by 6 pairs of arms that are
held together in the center of the IVC lumen by means of
a bioabsorbable filament. The filament is composed of poly-
p-dioxanone (PPDO), a synthetic polymer that degrades
naturally in vivo via hydrolysis and has been used in
biodegradable devices (sutures, for example) since the 1970s
[18]. The nitinol frame is designed to concentrically and
longitudinally distribute radial force in order to decrease
device tilting, migration, and perforation. Upon deployment,
the cylindrical frame expands to appose the IVC wall,
commencing incorporation and neointimal healing. The
bioabsorbable filament is designed to hydrolyze so that the
arms are released from the filtering cone and retract to
the IVC wall into a nonfiltering configuration. This design
allows temporary protection against PE, and following this
bioconversion leaves the IVC lumen patent. The Sentry is
indicated for use in IVCs with diameters between 16 and
28 mm. The filter comes preloaded in a loading tool, which
is attached to a custom introducer sheath for deployment.
It is suitable for a femoral or jugular approach. The filter
is advanced through the introducer sheath using a pusher,
which is supplied with the device. Once the device is at
the intended location, the pusher is held stationary and the
introducer sheath is retracted to execute deployment.
2.2. Animal Model. Sheep are known to be suitable anatomi-
cally and physiologically for the evaluation of cardiovascular
devices, including IVC filters, and have been used extensively
in preclinical studies [19–21].The coagulation systemof sheep
has been reported to be more similar to that of humans
than the coagulation systems of pigs or dogs, although a
tendency toward hypercoagulability has been reported with
the ovine model, based on hematological differences related
to platelet count and the size of red blood cells [21]. Suffolk
cross sheep were selected for this study, because previous
experience with this breed has shown that IVC diameter
tends to be larger than in other breeds and closer to the
vessel diameter indicated for the Sentry IVC filter (16 to 28
mm), thus ensuringmore representative clinical performance
evaluations. The sheep used in this study were all castrated
males (wethers) between 1 and 2 years of age and weighing
between 54.0 and 79.8 kg at the time of study device implant.
2.3. Study Design. The objectives of this preclinical study
were to assess technical performance with the Sentry IVC
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filter in terms of deployment, positioning in the IVC, confir-
mation of intended filtering configuration, and incorporation
following device bioconversion; to evaluate the early in vivo
response to the cylindrical filter frame and the late incorpora-
tion of the device into the IVCwall after 6months in vivo; and
to assess IVC filter-related complications through 6 months.
The studywas performed at Transitional Testing andTraining
Laboratories (T3 Labs, formerly St. Joseph’s Translational
Research Institute), Atlanta, GA, USA, in accordance with
the requirements of 21 CFR Part 58 (Good Laboratory Prac-
tice). Animal care (including purchase, transport, quarantine,
and acclimation; health and medication monitoring; use of
sedatives, analgesics, and anesthesia; and euthanasia) was
conducted in accordance with USDepartment of Agriculture
guidelines through the Animal Welfare Act (9 CFR Parts 1, 2,
and 3) and guidelines of the Institute of Laboratory Animal
Resources of the National Academy of Sciences and the
Association for Assessment and Accreditation of Laboratory
Animal Care International.
The study design is summarized in Figure 2. A total
of 24 bioconvertible study devices and 1 control retrievable
filter were implanted in the infrarenal IVC of 25 sheep,
with extensive daily monitoring and intensive imaging and
posttermination necropsy. The devices and animals were
treated and evaluated in two distinct cohorts: (1) early-
incorporation analysis cohort, for assessment of device per-
formance, bioconversion, and incorporation of the cylin-
drical frame, with termination and necropsy performed
≤98 days after implantation (n = 10 study devices); (2)
late-incorporation analysis cohort, for assessment of device
incorporation (cylindrical frame and retracted filter arms),
with termination and necropsy planned for 180± 30 days after
implantation (n = 14 study devices and 1 control device). All
24 Sentry devices implanted in the two study cohorts were
identical in terms of frame and filter arm design and the
material of the bioabsorbable filament.
The one control device implanted in the late-incorpora-
tion analysis cohort was an OptEase Retrievable Vena Cava
Filter (Cordis, Milpitas, CA, USA), a commercially available
device.
2.4. Treatment Procedure. Prior to enrollment, all sheep were
quarantined and acclimated. All animals were given seda-
tives, analgesics, and anesthesia medications in accordance
with the facility procedures. Heparin was administered as
needed to maintain an activated clotting time (ACT) of >300
seconds during the procedure.
Prior to implantation, percutaneous access was gained
and an introducer sheath was placed in either the right or
left femoral vein. Biplanar venography (anteroposterior and
lateral) was performed under respiratory apnea to determine
IVC diameter and assess vessel geometry to ensure suitability
for enrollment. The IVC diameter was determined by cal-
culating the average of the 2 measurements. A 5 Fr pigtail
catheter (Cook Medical, Bloomington, IN, USA) was used
for calibration purposes. Once the sheep met the inclusion
criteria, in terms of IVC geometry and diameter, the Sentry
introducer sheath was placed. One Sentry IVC filter was
deployed in the IVC of each animal in accordance with the
device instructions for use (IFU). Every effort was made to
only enroll animals that were within the indicated vessel
diameter range of 16 to 28 mm. Following implantation, all
cannulation sites were closed and the animals were recovered.
2.5. In-Life Monitoring. Animals were monitored daily to
check on feeding patterns, mental attitude, and physical
responsiveness. Temperature, pulse, and respiration (TPR)
checks and subjective objective assessment plans (SOAP)
were performed weekly.The SOAP included an assessment of
sheepmovement, feeding and stool, andmucousmembranes.
In the early-incorporation analysis cohort, X-ray follow-
up was performed at 45 (±3), 50 (±3), 60 (±3), 70 (±3), 90
(±10), and 100 (±10) days after implantation. In the late-
incorporation analysis cohort, weekly X-rays were performed
starting on day 46 (±3) after implantation. A portable X-ray
machine (MinXray HF 100, Northbrook, IL, USA) was used
with the animals humanely restrained in a standing position,
and no sedation was required. In the late-incorporation
analysis cohort, computed tomography (CT) was used to
evaluate bioconversion at 90, 120, and 180 days. At 180 days,
CT angiography was also performed. Prior to termination for
all animals in both cohorts, biplanar X-rays were obtained to
determine the filter bioconversion status.
2.6. Termination. Prior to termination, all animals were
sedated per standard facility procedures and an introducer
sheath was placed in the femoral vein. Venography was
performed on all animals. CT and CT venography were per-
formed on animals in the late-incorporation analysis cohort.
Heparin was administered as needed to maintain ACT at
>300 seconds during the termination procedure. Following
the in-life imaging, all animals were euthanized under deep
inhalant anesthesia, using 20 to 40 mEq potassium chloride
in accordance with the facility’s procedures, and were then
sent for necropsy.
2.7. Necropsy Assessment. All scheduled necropsy was per-
formed by a board-certified pathologist. The abdominal and
thoracic cavities were opened and a macroscopic evaluation
of the implant site was performed. The IVC was perfusion
fixed with 10% neutral buffered formalin (NBF). The lungs
were examined for gross evidence of pulmonary infarction,
and samples from each lobe were obtained and immersion
fixed in 10% NBF.
Representative sections of the following organs were
immersion fixed in 10% NBF and retained: spleen, heart,
liver, kidneys, brain, and local lymph nodes. Additional
organs were collected as deemed appropriate. All tissues were
imaged using standard digital photography. In addition, a
laparoscope was used to image the internal lumen of the IVC
section containing the device.
2.8. Histological Assessment. Histological assessment was
performed on all animals in the late-incorporation analysis
cohort (animals euthanized at 180 ± 30 days postimplan-
tation) by CVPath Institute (Gaithersburg, MD, USA). All
IVC sections containing IVC filters were imaged using
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Early-incorporation analysis cohort
n = 10 bioconvertible Sentry IVC filters
implanted in 10 sheep
X-ray imaging follow-up
• 45 ± 3 days • 60 ± 3 days
• 70 ± 3 days • 90 ± 10 days
100 ± 10 days
X-ray imaging follow-up
• Weekly beginning at 46 ± 3 days
CT to evaluate bioconversion
• 90 days • 120 days • 180 days
Animal termination at ≤102 days
• Bi-planar X-ray to determine
bioconversion status
• Pre-termination venography
Animal termination at 180 ± 30 days
• Bi-planar X-ray to determine
bioconversion status







n = 14 bioconvertible Sentry IVC filters
implanted in 14 sheep
n = 1 control OptEase retrievable filter
implanted in 1 sheep
25 Suﬀolk cross sheep
Figure 2: Study design.
high-contrast digital-based radiographs (Faxitron X-Ray
Corporation, Model LX-60, Lincolnshire, IL, USA). The
radiographs were used during sectioning and were also
examined for potential fractures.
All IVC sections containing IVC filters were processed
in a graded series of alcohols and xylenes. The IVCs were
embedded in resin and sections were prepared with a micro-
tome or ground using EXAKT (Oklahoma City, OK, USA)
Linear Grinding technology. Ground sections were stained
with toluidine blue/basic fuchsin, and sections prepared with
amicrotomewere stainedwith hematoxylin and eosin (H&E)
or Movat pentachrome.
Morphometric measurements were obtained for cross-
sectional areas, relative filter arm expansion, neointimal
thickness, and percent stenosis. Tissue incorporation along
the length of the IVC filters was evaluated, and the neointimal
coverage and apposition of the filter frame, arms, and tips
were assessed by semiquantitative analysis. Filter arms and
tips were also analyzed for the presence of residual PPDO
filament.The lungswere dehydrated in a graded series of alco-
hols and xylene.The sampleswere then embedded in paraffin,
sectioned on a rotary microtome, and stained with H&E.
2.9. Data and Statistical Analysis. Basic statistical analysis,
including the calculation of mean values and standard devia-
tions, was performedon relevant data tables using a registered
copy of Microsoft Excel.
3. Results
3.1. Filter Deployment and Initial Follow-Up. Since the IVC
tends to be oval [22], the IVCs of all sheep were measured
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Figure 3: Representative imaging for an animal from the late-incorporation analysis cohort. Left: venogram of the Sentry IVC filter on the
day of implantation. Middle: X-ray of the bioconverted filter. Right: CT reconstruction showing bioconversion of the Sentry IVC filter.
in both anteroposterior and lateral views, and the IVC
diameter was determined by calculating the average of the
2 measurements. Overall for the two cohorts the mean IVC
diameter was 17.3 mm (range 14.2 to 22.2 mm). All 25 devices
were accurately deployed as intended and were placed below
the renal veins in all cases. Upon implantation, the alignment
of the filters with the IVC wall was confirmed, with the filter
apex being visible and well centered (Figure 3).
After implantation, the animals were monitored at the
animal trial facility. One animal from the early-incorporation
analysis cohort died prematurely 8 days after implantation.
The gross necropsy assessment of the IVC, lungs, bladder,
kidneys, liver, spleen, heart, brain, and lymph nodes of this
animal reported a probable cause of death as septic emboli
related to lung abscess. The detailed histologic evaluation
on selected lung and myocardial tissue concluded that the
suspected cause of death was pulmonary infection leading
to a hypercoagulable state. The premature death was not
attributed to the Sentry IVC filter.
3.2. Early-Incorporation Analysis Cohort. The remaining 9
sheep from this cohort were terminated ≤98 days after
implantation—1 at 51 days after implantation, 1 at 89 days, 4
at 97 days, and 3 at 98 days. There was no evidence of any
device-related complications, and the IVCs were patent in all
animals.
During necropsy, all IVCs were assessed macroscopically
to determine the level of patency within the IVC and evaluate
the progression of incorporation ≤98 days after implantation.
In each case, a laparoscope was used to axially image the
IVC section containing the Sentry IVC filter, and the IVC
section containing the filter was cut longitudinally to facilitate
visual assessment of incorporation. The IVCs were patent in
all animals, with no caval thrombosis, the cylindrical frames
of the filters were well incorporated, and the filter arms had
retracted to the vessel wall, with incorporation commenced
but not yet complete. Figure 4 shows the unobstructed patent
lumen and the nearly complete incorporation of the filter
frame (which is almost invisible) from an animal that was
terminated 97 days after implantation.
Figure 4: IVC from an animal from the early-incorporation analysis
cohort terminated at 97 days. Laparoscopic imaging at necropsy
of IVC sections containing the Sentry IVC filter, showing the
unobstructed patent lumen and the nearly complete incorporation
of the filter frame.
3.3. Late-Incorporation Analysis Cohort. The sheep in this
cohort underwent CT follow-up at 104-112 days (falling
within the 120-day time window), at 139-147 days (falling
within the 150-day window), and at 174-189 days (the 180-
day window). Beginning with the 120-day CT imaging and
continuing with the 150-day and 180-day imaging, all of the
14 study devices were in nonfiltering configuration. The 180-
day CT venography demonstrated IVC lumen patency in all
of the study animals.
The animals in this cohort were terminated between 180
and 209 days after implantation. Pretermination venography
and CT/ CT venography of the control device, the OptEase
Retrievable Vena Cava Filter (the animal was terminated
on day 183 after implantation), identified no IVC filter-
related complications. The pretermination imaging showed
that all Sentry IVC filters were bioconverted (Figure 3) and
that the IVCs were patent with excellent flow. There was
no evidence of any device-related complications (no device
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Figure 5: Imaging of the IVC segments with the control OptEase device (terminated at 183 days). Left: preexplant digital photograph of
IVC sections with the implanted control OptEase Retrievable Vena Cava Filter. Right: a transverse section stained with toluidine blue/basic
fuchsin, demonstrating incorporation of the device into the wall of the IVC.
Figure 6: Representative images of IVC sections with the Sentry IVC filter (terminated at 184 days). Left: preexplant digital photograph of
IVC sections with the implanted Sentry device. Middle: laparoscopic image of IVC filter within the IVC, demonstrating lumen patency. Right:
transverse section stained with toluidine blue/basic fuchsin, demonstrating incorporation into the wall of the IVC. The green box indicates
mild neointimal proliferation.
tilting, fracture, migration, perforation, or IVC occlusion or
thrombus) and no evidence of IVC stenosis.
After termination of the animals and prior to explant
of the IVC sections with the implanted filters, digital pho-
tographs were obtained to evaluate the impact of the filter
on the surrounding tissue. Based on these images, it was
determined that the Sentry IVC filters were well tolerated by
the sheep, whereas there was significant transmural incorpo-
ration of the control OptEase device.
In laparoscopic imaging performed ex vivo to evaluate
patency of the IVC with the control OptEase device, the
cylindrical portions of the frame were found to be mostly
incorporated into the vessel wall. The filtering apices of this
control device were within the IVC lumen, and the caudal
apex was associated with adherent fibrotic tissue. Overall, the
OptEase device produced notable overstretch of the IVCwall,
producing a star-shapedmorphology, withmoderate stenosis
and thickness in the central lumen (Figure 5).
The ex vivo laparoscopic examination of IVC segments
with the Sentry device was for evidence of perforation or
hemorrhage, for the incorporation of the filter frame, for
the apposition of the filter arm tips to the IVC wall, and
for biological material at the filter arm tips. There was no
evidence of perforation or hemorrhage in any of the animals,
and the filter frames were fully incorporated in all cases
(Figure 6).
Histological analysis demonstrated that the cylindrical
portions of the Sentry IVC filter frames were covered by
neointima, with the exception of some uncovered portions,
which were generally near tributary vessels. The devices
were stably incorporated into the wall of the IVC, with
minimal inflammation and good endothelialization. The
retracted filter arms demonstrated good integration into
the wall of the IVC. Residual filament was visible at the
eyelets in some devices and there was mild inflammation
consisting of macrophages near the filament. Figure 7 shows
a representative section through the tips of the filter arms,
stained with H&E, and a high-power magnification image
of residual PPDO filament, surrounded by chronic inflam-
matory cells. The residual filament was located adjacent to
the fully incorporated tip of a filter arm. None of the organ
sections including the lung sections showed any emboli or
evidence of filament.
4. Discussion
Employing extensive clinical and imaging-intense follow-up
(before and after animal termination) in an ovine model,
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Figure 7: Representative high-power images from the histological analysis of the integration of the Sentry filter arms into the wall of the IVC.
Left: section cut through the tips of the filter arms, stained with H&E. Right: view of residual PPDO filament material, surrounding chronic
inflammatory cells adjacent to the fully incorporated tip of a filter arm (dark red box in the image at left).
this experimental study provides support for the utility
of the Sentry IVC filter and the realization of the device
concept of protecting against PE during periods of transient
risk and then leaving a patent vessel lumen without the
need for secondary interventions to perform retrieval. In
all 24 animals that received study devices, deployment and
positioning in the filtering configuration in the center of the
IVC lumen were successful, and pre- and posttermination
examinations confirmed that all filters had bioconverted as
intended, leaving the IVC lumens patent. For the animals
with termination at ≤98 days, final in-life venography and
necropsy showed that the stabilizing cylindrical part of the
Sentry frame was incorporated in the vessel wall, and the
filter arms were retracted. For the animals with termination
at 180 ± 30 days, the final in-life imaging, necropsy, and
histopathology confirmed that the filter arms as well as
frames were stably incorporated and that the IVC lumens
were unobstructed and patent. Through 180 days, there were
no filter-related complications.
Retrievable IVC filters were developed to meet the need
for transient protection from PE in patients with tempo-
rary contraindications to anticoagulants [6]. Considerable
research supports the premise that the period of highest risk
for PE is relatively early for individuals in such situations. In
one study in a group of trauma patients, the average time
from injury to PE was determined to be 7.9 days [23], and
other studies have found that the majority of trauma-related
PE occurred less than 30 days after the index event [24, 25].
In studies of postoperative PE, the mean time from surgery
to PE was 3 to 20 days [8, 26, 27]. The majority of in-patient
PE events after orthopedic surgery occur within 35 days
after the procedure [28, 29]. When the transient period of
highest PE risk has passed, retrieval can reduce the incidence
of long-term complications associated with indwelling IVC
filters—such as caval thrombosis, DVT, perforation, and filter
fracture [30–33].
However, the increasing use of retrievable IVC filters
has brought some important safety and practical issues
into focus. The need to develop devices that will effectively
trap emboli but then be readily retrievable has resulted in
relatively unstable conical-type designs that demonstrate less
secure implantation than the permanent filters [34]. These
design compromises have led to complications such as tilting,
migration, and fracture [30, 34]. In practice, retrieval rates
remain low, despite FDA engagement. A retrospective review
performed by Angel et al. reported an average retrieval
rate of 34% in 6834 patients (range 12% to 45%) across
37 clinical studies [4]. One study demonstrated that even
with a dedicated filter registry only 59% of filters could be
successfully removed [35].
The in vivo studies demonstrate that the cylindrical
design of the nitinol frame of the Sentry IVC filter provides
stability in apposition to the wall of the IVC that is not
provided by retrievable filters, thus reducing complications
such as tilting andmigration. Incorporation of the cylindrical
portion of the frame is advanced by 100 days after implan-
tation, while the filter arms are stably incorporated into the
vessel wall by 180 days after implantation. The laparoscopic
and histological assessment provides corroborating support
regarding the full degree of filter endothelialization and vessel
patencywith no evidence of IVC stenosis, thus demonstrating
the restoration of normal tissue function by 180 days.
IVC filters are designed to capture thrombus. Studies
by Singer et al. employing computational fluid dynamics
(CFD) indicate that the flow disturbances initiated by IVC
filters can cause regions of stagnation, which can potentially
contribute to thrombosis and caval occlusion [36, 37]. In
the PREPIC (Pre´vention du Risque d’Embolie Pulmonaire
par Interruption Cave) randomized trial evaluating the long-
term outcomes of patients with proximal DVT, investigators
concluded that the 8-year incidence of recurrent DVT was
significantly higher in the group of 200 patients implanted
with permanent IVC filters than in the 200 patients who did
not receive filters [33]. The direct cause of the increased rate
of DVT is not clear, but it is conceivable that long-term filter-
induced flow disturbances had a contributory effect [36, 37].
The concept of “leaving nothing behind” after percu-
taneous interventions, which has emerged in recent years
with the development of biodegradable stents [38], has an
appeal for the prevention of PE, considering the transient
nature of the need for protection in the majority of patients
receiving IVC filters and the high complication rates when
timely device retrieval does not occur [16]. The PREPIC trial
and the CFD analyses performed by Singer et al. highlight
the benefits of restoring normal blood flow in the IVC after
the risk of PE has passed. The Sentry IVC filter design
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allows timely disassembly of the filtering mechanism, leaving
nothing behind in the lumen of the IVC to obstruct blood
flow. The body’s normal healing processes, combined with
the nitinol frame design of the Sentry device, support the
restoration of normal tissue function within the IVC. The
Sentry IVC filter thereby offers the benefits of a retrievable
IVC filter, without the burden and cost of a second procedure,
the design compromises required to facilitate retrieval, or the
risks of nonretrieval.
This preclinical study employed extensive imaging-
intense follow-up—involving scheduled X-ray, CT, CT
venography, and venography. Comparatively, it was found
that X-ray was effective for assessing device filtering config-
uration and bioconversion status with filter arm separation
from the filament cone, that CT was useful for assessing the
retraction status of the filter arms in terms of their separation
from the cone and from each other, and that CT venography
could be utilized to identify thrombus and (in combination
with plain CT) to determine the adjacency of the filter arm
tips to the IVC wall. Venography was useful for identifying
thrombus and patency of and blood flow in the IVC lumen,
but it was of limited use for determining the positions of filter
arm tips.
The limitations of this study include the fact that there
is no definitive evidence to support the assumption that the
sheep IVC represents a valid model of the human IVC, and
all findings (positive and negative) in the model can only
serve as inferences with respect to the performance of the
study device in humans. However, the model justification
process for the study carefully considered the comparability
to humans of the sheep model relative to other models
such as dogs and pigs, in terms of features including overall
size and IVC diameter (which was optimized by selection
of the Suffolk cross breed), respiration rate, cardiac output,
temperature, and blood characteristics. The tendency toward
hypercoagulability in the sheep model was noted, and the
investigators also noted that the sheep anatomy provided a
greater challenge than in humans for deployment, due to
extreme bending of the introducer sheath imposed by the
groin geometry. The rate of hydrolysis of the PPDO filament
is directly dependent on temperature, and human blood
temperatures are lower than ovine blood temperatures [39].
Therefore, bioconversion times in an ovine model are not
representative of device opening times in vitro, and while X-
rays were performed during the animal studies to understand
the process of bioconversion, the data collected were not
used to establish the time to opening of the device. The
sample size of 24 animals implanted with study devices,
while small in comparison with some human studies, was
comparable to or greater than in preclinical studies of other
(retrievable) IVC filters. The 180-day duration of the study
allowed demonstration of component endothelialization and
device stability [19, 20, 40, 41].
5. Conclusions
With extensive imaging-intense follow-up, this preclinical
study in a sheep model provided important information
about the technical performance, bioconversion, and stages
of incorporation of the Sentry IVC filter. The preclinical
study supports the premise that the Sentry IVC filter design
allows timely disassembly of the filtering mechanism, leav-
ing nothing behind in the lumen of the IVC to obstruct
blood flow. A prospective multicenter pivotal investigational
device exemption trial of the Sentry IVC filter is ongoing
(NCT01975090).
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